Welcome
Support Centre
02 September 2010 
ISRCTN Register - International Standard Randomized Controlled Trial Number
Trial registration
Unique identification scheme
International databases
home  |   my details  |   ISRCTN Register  |   mRCT  |   links  |   information  |   press
Find trials
ISRCTN Register
tips on searching

Registration
New application
Updating record

Information
introduction
governing board
ISRCTN FAQs
data set
letter of agreement
request information
guidance notes

[ Print-friendly version ]
A randomised study of continuous infusional 5-Fluorouracil (5FU) with or without mitomycin-C in patients with neuroendocrine tumours
ISRCTN ISRCTN53478221
ClinicalTrials.gov identifier
Public title A randomised study of continuous infusional 5-Fluorouracil (5FU) with or without mitomycin-C in patients with neuroendocrine tumours
Scientific title
Acronym N/A
Serial number at source RMH E/N 1169
Study hypothesis To compare the response rate and quality of life in patients having these regimens.
Ethics approval Not provided at time of registration
Study design Randomised controlled trial
Countries of recruitment United Kingdom
Disease/condition/study domain Neuroendocrine tumours
Participants - inclusion criteria 1. Histological evidence of neuroendocrine tumours not amenable to surgery or radiotherapy
2. Patients evaluable for response must have bi-dimensionally measurable disease as assessed by chest X-ray or computed tomography (CT) scan
3. This disease must be outside previously irradiated areas
Participants - exclusion criteria Not provided at time of registration
Anticipated start date 12/09/1995
Anticipated end date 26/11/2003
Status of trial Completed
Patient information material
Target number of participants Not provided at time of registration
Interventions Two arms:
Regimen 1. Protracted venous infusion (PVI) 5FU 300 mg/m2/day over 24 weeks
Regimen 2. PVI 5FU 300 mg/m2/day over 24 weeks Mitomycin-C 7 mg/m2 (total dose must not exceed 56 mg) four courses over 24 weeks
Primary outcome measure(s) 1. Response rate
2. Toxicity
3. Time to disease progression
4. Survival
5. Quality of life
Secondary outcome measure(s) No secondary outcome measures
Sources of funding Royal Marsden Hospital (UK)
Trial website
Publications
Contact name Prof  David  Cunningham
  Address Department of Medicine
Royal Marsden NHS Trust
Downs Road
Sutton
  City/town Surrey
  Zip/Postcode SM2 5PT
  Country United Kingdom
Sponsor The Royal Marsden NHS Foundation Trust (UK)
  Address Downs Road
  City/town Sutton
  Zip/Postcode SM2 5PT
  Country United Kingdom
  Tel +44 (0)20 8661 3156
  Fax +44 (0)20 8643 9414
  Email
Date applied 19/08/2002
Last edited 19/05/2008
Date ISRCTN assigned 19/08/2002
Submit your trial protocol
Submit to Trials journal
Follow us on Twitter
© 2010 ISRCTN unless otherwise stated.


BioMed Central